10-Q: Modular Medical Reports Q2 2026 Results, Faces Going Concern Doubt

Modular Medical, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued operating losses and substantial doubt regarding its ability to continue as a going concern.

Summary

• Modular Medical, Inc. reported its financial results for the quarter ended June 30, 2026.
• The company experienced a net loss of $6.486 million for the quarter, compared to a net loss of $6.702 million in the same period of 2025.
• Total operating expenses decreased by 3.9% to $6.538 million from $6.804 million in the prior year's quarter.
• Research and development expenses decreased by 14.9% to $4.371 million, while selling, general, and administrative expenses increased by 29.8% to $2.167 million.
• As of June 30, 2026, the company had cash and cash equivalents of $3.920 million and an accumulated deficit of $119.481 million.
• The company continues to face substantial doubt about its ability to continue as a going concern, necessitating future capital raises.
• Commercial availability of the Pivot product was announced in June 2026, with initial shipments commencing.
• The company completed a registered direct offering in April 2026 and has an active at-the-market offering program.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the company's continued substantial doubt about its ability to continue as a going concern, significant net losses, and reliance on future capital raises.

Positives

• Commercial availability of the Pivot product was announced in June 2026, with initial shipments commencing.
• The company completed a registered direct offering in April 2026, raising approximately $3.0 million in net proceeds.
• The company has an active at-the-market offering program, which provided $0.7 million in proceeds in June 2026 and $5.1 million in subsequent proceeds after the quarter end.
• Research and development expenses decreased by 14.9% to $4.371 million, indicating some cost control in this area.

Negatives

• The company incurred a net loss of $6.486 million for the three months ended June 30, 2026.
• The company has substantial doubt about its ability to continue as a going concern within one year.
• Cash and cash equivalents decreased to $3.920 million as of June 30, 2026, from $6.942 million as of March 31, 2026.
• The accumulated deficit increased to $119.481 million as of June 30, 2026.
• Selling, general, and administrative expenses increased by 29.8% to $2.167 million.
• The company's independent registered public accounting firm expressed substantial doubt about its ability to continue as a going concern in its report for the year ended March 31, 2026.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern within one year from the issuance date of the financial statements.
• The company's future success depends on its ability to raise additional capital through debt or equity, and there is no certainty that such capital will be available on acceptable terms.
• If additional capital is not obtained, the company may be required to curtail product commercialization, research and development initiatives, and take additional cost-reduction measures.
• The company has not generated revenues to cover operating expenses and expects to continue incurring operating losses and negative cash flows.
• The company faces risks related to competition, financing, liquidity requirements, rapidly changing customer requirements, limited operating history, and market volatility.
• Issuing additional securities to raise funds may result in dilution for current stockholders.
• The company's ability to commercialize its products, competing technological developments, and the need for collaborations or acquisitions are critical factors for future capital requirements.

Future Outlook

The company expects research and development expenses to remain consistent for the remainder of fiscal 2027. Selling, general, and administrative expenses are expected to increase in fiscal 2027 due to expansion of sales and marketing and increased general and administrative headcount to support product commercialization. The company's ability to continue as a going concern is dependent on raising additional capital.

Management Comments

• Management believes that its current operating plan, combined with its cash position, raises substantial doubt about its ability to continue as a going concern.
• Management expects to continue to incur operating losses and negative cash flows for the foreseeable future.
• Management expects operating expenses to increase as the company invests in development and commercialization.
• Management concluded that disclosure controls and procedures were effective as of June 30, 2026.

Industry Context

StockSavvy.ai notes that the medical device industry, particularly in the diabetes management sector, is highly competitive and capital-intensive. Companies like Modular Medical often face long development cycles, rigorous regulatory hurdles (like FDA clearance), and significant market adoption challenges. The focus on a simplified patch pump aims to address a broader market segment beyond 'super users,' which is a strategic move to capture a larger share of the growing diabetes device market.

Comparison to Industry Standards

• The company's net loss of $6.486 million for the quarter is substantial for a commercial-stage company, indicating a high burn rate relative to its current revenue generation, which is not yet established.
• The significant accumulated deficit of $119.481 million is common for early-stage medical device companies investing heavily in R&D and commercialization, but it highlights the critical need for successful future funding rounds.
• The reliance on at-the-market (ATM) and registered direct offerings for capital is a standard practice for companies in this stage, but the amounts raised ($3.0M in April 2026, $0.7M in June 2026, and $5.1M post-quarter) are modest relative to the ongoing operational losses, underscoring the going concern risk.
• The decrease in R&D expenses and headcount, while potentially a cost-saving measure, could also signal a shift in focus or resource allocation that needs to be monitored for its impact on future product development and innovation compared to industry peers who may be increasing R&D investment.

Legal Proceedings

• The company is not currently involved in any litigation that it believes could have a material adverse effect on its financial condition or results of operations.

Related Party Transactions

• A family member of an executive officer converted from employee to consultant in April 2026, receiving compensation of approximately $1,100 for the three months ended June 30, 2026.
• A second family member of an executive officer is an employee, receiving compensation of approximately $18,900 for the three months ended June 30, 2026.
• A royalty agreement exists with the founder (an executive officer) for intellectual property, entitling him to royalty payments on product sales, capped at $10,000,000 total.

Stakeholder Impact

• Shareholders face significant risk of dilution from future capital raises and the potential loss of their investment if the company cannot continue as a going concern.
• Employees may face uncertainty regarding job security due to the company's financial condition and potential need for cost reductions.
• Creditors and suppliers may face risks related to the company's ability to meet its financial obligations.
• Customers may be impacted if the company's ability to commercialize and support its products is hindered by financial constraints.

Next Steps

• Expand commercial activities for its Pivot product across metropolitan markets.
• Obtain regulatory clearance to market and sell its Pivot product in foreign jurisdictions.
• Improve the manufacturability and usability of its Pivot product.
• Develop new pump products.
• Continue to seek additional financing to support future operations.

Key Dates

Recommendation

The filing indicates significant financial distress, with substantial doubt about the company's ability to continue as a going concern. Despite product development progress, the ongoing net losses, declining cash reserves, and critical need for further capital raises present a high-risk profile. The potential for dilution and the uncertainty of future funding make it a speculative investment at this time.

Keywords

insulin pump, medical device, diabetes, FDA clearance, commercialization, capital raise, going concern, registered direct offering